Genomic Solutions Brings Losses, Tumbling Stock for Harvard Bioscience | GenomeWeb

Harvard Bioscience last week reported that its Genomic Solutions business was a “major disappointment” in the first quarter of 2004, and that the company may consolidate the business to cut costs — announcements that sent its stock plunging by 50 percent during the week.

Genomic Solutions took in $2 million less than expected, according to the company — pushing Harvard Bioscience out of the profitability zone. The company experienced a net loss of $51,000 for the quarter, compared with a net income of $776,000 in the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.